Bristol-Myers
Squibb, or simply the BMS, an American Pharma giant has now lost its veteran of 12 years, Douglas Manion. Mr.Manion has most recently served as SVP as the head of specialty development at BMS and previously headed the virology department at the company.Manion quit Bristol early last week to become the CEO of Kleo Pharmaceuticals. He is expected to head the biotech’s work in an attempt to pioneer a new class of immunotherapies using small molecules to help a patient’s immune system fight against both cancers and infectious diseases.
Kleo Labs is a Connecticut-based upstart got off its series A last fall, led by Biohaven. Manion takes over from co-founder David Spiegel, a professor of chemistry and pharmacology at Yale University, who will instead take on the role of president at Kleo Pharmaceuticals.
“I am thrilled to join Kleo Pharmaceuticals as it accelerates its quest to provide novel immunotherapies for patients with high unmet medical need. The science is so compelling. I look forward to partnering with the scientists at Kleo led by David Spiegel and the rest of the team, in advancing a truly innovative approach to enlist patients’ own immune systems to fight serious disease.” said Mr.Manion
“Doug brings an incredible wealth of drug discovery and development expertise and experience to the Kleo team. Without a doubt, the addition of Doug will further accelerate Kleo’s place as a leader in the field of immunotherapy be it in cancer, infectious diseases or other areas of high unmet medical need.” Says the M.D of Kleo Pharmaceuticals, Declan Doogan.
